Skip to main content

Table 5 Multivariate Cox regression analysis A) for HER2, B) for TOP2A and C) for both HER2 and TOP2A, adjusted for significant clinicopathological parameters in terms of DFS and OS

From: HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

   Disease-free survival Overall survival
   HR 95% C.I. Wald's p HR 95% C.I. Wald's p
A) Group       
     E-CMF vs E-T-CMF 1.07 0.72-1.59 0.75 1.58 0.96-2.60 0.071
  Tumor size       
     2-5 cm vs < 2 cm 1.62 0.99-2.67 0.056    
     > 5 cm vs < 2 cm 1.73 0.92-3.22 0.087    
  Adjuvant HT       
     Yes vs No 0.50 0.27-0.94 0.031    
  Nodal involvement       
     ≥ 4 vs 0-3 2.16 1.19-3.93 0.011 1.83 0.92-3.61 0.082
  Hormone receptor status       
     Positive vs Negative     0.54 0.30-0.94 0.030
  Ki67       
     High vs Low 1.69 0.91-3.15 0.096 3.54 1.27-9.84 0.015
  HER2 (mRNA)       
     High vs Low 1.68 1.10-2.58 0.016 1.77 1.04-3.02 0.035
B) Group       
     E-CMF vs E-T-CMF 1.20 0.79-1.82 0.40 1.58 0.96-2.60 0.071
  Nodal involvement       
     ≥ 4 vs 0-3 3.03 1.56-5.85 0.001 2.21 1.11-4.38 0.024
  Hormone receptor status       
     Positive vs Negative 0.49 0.31-0.78 0.003 0.42 0.24-0.71 0.001
  Ki67       
     High vs Low 2.04 1.05-3.97 0.035 3.50 1.25-9.76 0.017
  TOP2A (CISH)       
     Amplified vs Non-amplified 0.29 0.09-0.93 0.038    
  TOP2A (mRNA)       
     High vs Low     2.08 1.24-3.47 0.005
C) Group       
     E-CMF vs E-T-CMF 1.17 0.74-1.84 0.51 1.60 0.97-2.64 0.065
  Nodal involvement       
     ≥ 4 vs 0-3 2.82 1.39-5.71 0.004 2.09 1.05-4.16 0.036
  Hormone receptor status       
     Positive vs Negative 0.56 0.33-0.96 0.035 0.49 0.28-0.86 0.014
  Ki67       
     High vs Low 2.24 1.01-4.98 0.048 3.18 1.13-8.92 0.028
  HER2 (mRNA)       
     High vs Low 1.80 1.10-2.93 0.019 1.73 1.02-2.93 0.040
  TOP2A (CISH)       
     Amplified vs Non-amplified 0.36 0.11-1.17 0.091    
  TOP2A (mRNA)       
     High vs Low 1.52 0.97-2.41 0.070 2.06 1.23-3.46 0.006
  1. HT, hormonotherapy